HERON THERAPEUTICS INC DE
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
HRTX$0.37+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net income (loss) | $2,635 | $(3,160) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,511 | 3,375 |
| Depreciation and amortization | 551 | 689 |
| Amortization of debt discount | 158 | 88 |
| Amortization of debt issuance costs | 53 | 52 |
| Accretion of discount on short-term investments | (281) | (638) |
| Retirement and impairment of property and equipment | — | 170 |
| Gain on disposal of property and equipment | (34) | — |
| Change in operating assets and liabilities: | ||
| Accounts receivable | 145 | (5,185) |
| Inventory | (3,772) | (363) |
| Prepaid expenses and other assets | (8,604) | (222) |
| Accounts payable | 624 | (2,403) |
| Accrued clinical and manufacturing liabilities | (5,466) | (2,347) |
| Accrued payroll and employee-related liabilities | (3,103) | (1,577) |
| Other accrued expenses | 5,713 | 2,005 |
| Net cash used in operating activities | (8,870) | (9,516) |
| Investing activities: | ||
| Purchases of short-term investments | (22,902) | (37,892) |
| Maturities and sales of short-term investments | 25,242 | 39,170 |
| Purchases of property and equipment | (109) | — |
| Proceeds from the sale of property and equipment | 42 | — |
| Net cash provided by investing activities | 2,273 | 1,278 |
| Financing activities: | ||
| Receipts for stock issued under the equity incentive plan | 64 | 11 |
| Net cash provided by financing activities | 64 | 11 |
| Net decrease in cash and cash equivalents | (6,533) | (8,227) |
| Cash and cash equivalents at beginning of period | 25,802 | 28,677 |
| Cash and cash equivalents at end of period | $19,269 | $20,450 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $636 | $649 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.